Evidence map›Paper›PMID 42118306›Full record

Observational studyAnnals of hematology2026

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera - German real-world data (PaVe study).

Martin Griesshammer, Eyck von der Heyde, Rudolf Schlag, Burkhard Schmidt, Steffi Weniger, Michael Koenigsmann, Martina Stauch, Eva Gückel, Volker Baum, Rudolf Weide

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martin GriesshammerUniversity Clinic for Hematology and Oncology, Johannes Wesling Clinic Minden, University Bochum, Minden, Germany. Martin.Griesshammer@muehlenkreiskliniken.de.
Eyck von der HeydeOncology at Raschplatz, Hannover, Germany.
Rudolf SchlagHematology-Oncology Specialist Practice, Würzburg, Germany.
Burkhard SchmidtHematology and Oncology München-Pasing MVZ GmbH, München, Germany.
Steffi WenigerCollective Practice, Erfurt, Germany.
Michael KoenigsmannOncology Outpatient Center, Hannover, Germany.
Martina StauchOutpatient Center for Hematology, Oncology and Coagulation, Kronach, Germany.
Eva GückelNovartis Pharma GmbH, Nürnberg, Germany.
Volker BaumNovartis Pharma GmbH, Nürnberg, Germany.
Rudolf WeideInVo, Institute for Health Services Research Oncology GbR, Koblenz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib, a JAK1/JAK2 inhibitor, has demonstrated efficacy in achieving hematocrit control, spleen volume reductions, and symptom improvement in patients with polycythaemia vera (PV) resistant to or intolerant of hydroxyurea in clinical trials. PaVe is a prospective, noninterventional study of patients with PV who received ruxolitinib in a real-world setting in Germany. Observational parameters included effectiveness, safety, patient satisfaction and quality of life. Patients with and without prior treatment with ruxolitinib were included in this study. Additionally, patients were stratified by no/high risk. The study was primarily analyzed using descriptive methods. Four hundred and thirty-three patients with PV were included in this study, of which 62% were pretreated with a JAK-inhibitor and 38% were not. Mean decreases from Baseline in hematocrit levels/leukocyte counts at the last assessment were more pronounced in naïve patients (-6.2% versus - 1.6%/-4.5 × 10

Indexed as

Polycythemia VeraPyrazolesAdultAgedAged, 80 and overFemaleGermanyHematocritHumansMaleMiddle AgedNitrilesProspective StudiesPyrimidinesQuality of LifeTreatment OutcomeNitrilesPyrazolesPyrimidinesruxolitinibPaVe non-interventional studyPolycythemia veraReal-world evidenceRuxolitinib

Identifiers

PMID42118306
PMCPMC13167810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.